| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1039164040 |
| P356 | DOI | 10.1186/1471-230X-7-25 |
| P932 | PMC publication ID | 1925103 |
| P698 | PubMed publication ID | 17610716 |
| P2093 | author name string | Dale Rublee | |
| Philip Jacobs | |||
| Michael Loyd | |||
| P2860 | cites work | The role of endoscopy in dyspepsia | Q77301034 |
| US and UK health economics: two disciplines separated by a common language? | Q77322970 | ||
| Estimating the cost of lost productivity in dyspepsia | Q77397975 | ||
| Selective outpatient management of upper gastrointestinal bleeding in the elderly | Q77424181 | ||
| Ten-year prognosis of stroke and risk factors for death in a Japanese community: the Hisayama study | Q79074568 | ||
| Urgent vs. elective endoscopy for acute non-variceal upper-GI bleeding: an effectiveness study | Q80270802 | ||
| Cost of stroke in Sweden: an incidence estimate | Q80784258 | ||
| Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis | Q24555478 | ||
| Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis | Q24655364 | ||
| Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group | Q28138338 | ||
| Gastroduodenal Safety of Cyclooxygenase-2 Inhibitors | Q28165573 | ||
| Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs | Q28166597 | ||
| Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographics | Q28169144 | ||
| Trends in acute coronary heart disease mortality, morbidity, and medical care from 1985 through 1997: the Minnesota heart survey | Q28186036 | ||
| Recommendations for the appropriate use of anti-inflammatory drugs in the era of the coxibs: defining the role of gastroprotective agents | Q28192894 | ||
| Are selective COX 2 inhibitors superior to traditional NSAIDs? Pharmacia's response to editorial | Q28193474 | ||
| Are selective COX 2 inhibitors superior to traditional NSAIDs? Both the CLASS and VIGOR trials support the COX 2 hypothesis | Q28193475 | ||
| Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials | Q28193800 | ||
| Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases | Q28193996 | ||
| Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study | Q28195282 | ||
| The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis | Q28196146 | ||
| Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib | Q28199107 | ||
| Risk of Upper Gastrointestinal Injury and Events in Patients Treated With Cyclooxygenase (COX)-1/COX-2 Nonsteroidal Antiinflammatory Drugs (NSAIDs), COX-2 Selective NSAIDs, and Gastroprotective Cotherapy: An Appraisal of the Literature | Q28200737 | ||
| Comparison of inpatient and outpatient upper gastrointestinal haemorrhage | Q28210405 | ||
| Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs--nice or necessary? | Q28211173 | ||
| Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial | Q28211411 | ||
| The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis | Q28211833 | ||
| The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults | Q28212030 | ||
| Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction | Q28214120 | ||
| The American College of Gastroenterology Bleeding Registry: preliminary findings | Q28240091 | ||
| Researchers deny any attempt to mislead the public over JAMA article on arthritis drug | Q28345729 | ||
| Low-dose diclofenac, naproxen, and ibuprofen cohort study | Q28369596 | ||
| Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study | Q29620671 | ||
| Upper gastrointestinal bleeding in an open-access dedicated unit | Q30492359 | ||
| Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials | Q32166686 | ||
| Outpatient care of selected patients with acute non-variceal upper gastrointestinal haemorrhage | Q33173846 | ||
| Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. | Q33178529 | ||
| The cost-effectiveness of a cardiovascular risk reduction program in general practice. | Q33576206 | ||
| Epidemiology of NSAID induced gastrointestinal complications. | Q33606443 | ||
| The clinical course and prognostic determinants of non-ulcer dyspepsia: a literature review | Q33707126 | ||
| Incidence and occurrence of total (first-ever and recurrent) stroke | Q33785546 | ||
| Review article: acid suppression in non-variceal acute upper gastrointestinal bleeding. | Q33792368 | ||
| ABC of the upper gastrointestinal tract: implications of dyspepsia for the NHS. | Q33807215 | ||
| Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Problems compromise review's validity | Q33813806 | ||
| Work loss costs due to peptic ulcer disease and gastroesophageal reflux disease in a health maintenance organization | Q33858591 | ||
| Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland | Q33940747 | ||
| Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s | Q33974678 | ||
| An evidence-based approach to prescribing NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis: The Second Canadian Consensus Conference | Q34048817 | ||
| Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs | Q34093824 | ||
| Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient | Q34141269 | ||
| Relation of upper gastrointestinal bleeding to non-steroidal anti-inflammatory drugs and aspirin: a case-control study | Q34394177 | ||
| Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation | Q34471706 | ||
| Impact of functional dyspepsia on quality of life and health care consumption after cessation of antisecretory treatment. A multicentre 3-month follow-up study | Q34504510 | ||
| Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies | Q34505003 | ||
| Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk | Q34518911 | ||
| The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis | Q34558759 | ||
| An evidence-based evaluation of the gastrointestinal safety of coxibs | Q34574384 | ||
| Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial | Q34720605 | ||
| Epidemiology of hospitalization for acute upper gastrointestinal hemorrhage: a population-based study. | Q34723164 | ||
| A meta-analysis of quality-of-life estimates for stroke | Q35056737 | ||
| Gastrointestinal effects of NSAIDs and coxibs | Q35072859 | ||
| Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors | Q35083808 | ||
| Risk factors for ulcer development in patients with non-ulcer dyspepsia: a prospective two year follow up study of 209 patients | Q35594762 | ||
| Systemic review: the prevalence and clinical course of functional dyspepsia | Q35691933 | ||
| Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations | Q35873867 | ||
| Epidemiology and economics of NSAID-induced gastropathy | Q36061476 | ||
| Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study | Q36247207 | ||
| Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. | Q36591918 | ||
| Long term acid suppressing treatment in general practice | Q36885144 | ||
| Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population. | Q45236722 | ||
| Cardiovascular events associated with long-term use of celecoxib, rofecoxib and meloxicam in Taiwan: an observational study. | Q45258184 | ||
| Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study | Q45260921 | ||
| Assessing the cost-effectiveness of COX-2 specific inhibitors for arthritis in the Veterans Health Administration | Q45333145 | ||
| Dyspepsia management in primary care: a decision analysis of competing strategies. | Q45980562 | ||
| The epidemiology of NSAID gastropathy: the ARAMIS experience | Q46209275 | ||
| Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models | Q46245351 | ||
| Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study | Q46481473 | ||
| Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications | Q46792133 | ||
| Recent considerations in nonsteroidal anti-inflammatory drug gastropathy | Q46924071 | ||
| Predictors of acute hospital costs for treatment of ischemic stroke in an academic center | Q48247946 | ||
| Long-term risk of recurrent stroke after a first-ever stroke. The Oxfordshire Community Stroke Project. | Q50606100 | ||
| Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs. | Q50616830 | ||
| Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. | Q50643607 | ||
| Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. | Q50663259 | ||
| Five-year survival after first-ever stroke and related prognostic factors in the Perth Community Stroke Study. | Q50664637 | ||
| Health impact of peptic ulcer in the United States. | Q50958881 | ||
| Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. | Q50960330 | ||
| Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. | Q52933446 | ||
| Evaluation of the dyspeptic patient: a cost-utility study. | Q53596290 | ||
| Assessing the Clinical and Economic Burden of Coronary Artery Disease: 1986-1998 | Q56928569 | ||
| Outpatient management of upper digestive hemorrhage not associated with portal hypertension: a large prospective cohort | Q57754057 | ||
| Long-term survival and causes of death after stroke | Q61457217 | ||
| The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis: a prospective 13 year study of 2131 patients | Q64112284 | ||
| Cost-effectiveness of alternative medications in the treatment of duodenal ulcer | Q67985132 | ||
| Bleeding peptic ulcer: a prospective evaluation of risk factors for rebleeding and mortality | Q68756451 | ||
| Introduction to the epidemiology of dyspepsia | Q69871446 | ||
| Report from the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceuticals: Canada | Q70914074 | ||
| Non-ulcer dyspepsia in the long-term perspective | Q70933528 | ||
| The natural course of peptic ulcer disease and its predictors | Q72121097 | ||
| Late outcome of bleeding gastric ulcer. Five to eight years' follow-up | Q72580482 | ||
| Prognostic factors in upper gastrointestinal bleeding | Q72673847 | ||
| Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs | Q72674958 | ||
| Risk assessment in upper gastrointestinal haemorrhage: implications for resource utilisation | Q73012987 | ||
| The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies | Q73122940 | ||
| Hospitalization for peptic ulcer bleeding: evaluation of a risk scoring system in clinical practice | Q73356243 | ||
| Managing patients with acute, nonvariceal gastrointestinal hemorrhage: development and effectiveness of a clinical care pathway | Q73485587 | ||
| What is the long-term outcome of the different subgroups of functional dyspepsia? | Q73686102 | ||
| Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo | Q74214651 | ||
| Incidence and risk factors for self-reported peptic ulcer disease in the United States | Q74376084 | ||
| Ten year mortality in patients with suspected acute myocardial infarction | Q36885318 | ||
| Epidemiology of recurrent cerebral infarction: a medicare claims-based comparison of first and recurrent strokes on 2-year survival and cost. | Q38501021 | ||
| Nonsteroidal antiinflammatory drug-induced ulcers: management by traditional therapies | Q38596301 | ||
| The Quality of Well-being Scale. Applications in AIDS, cystic fibrosis, and arthritis | Q38596707 | ||
| Management in general practice of patients with persistent dyspepsia. A decision analysis | Q39451238 | ||
| Economic assessment of peptic ulcer disease treatments | Q39472333 | ||
| The Swedish ACCES model: predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis | Q40716385 | ||
| Use of the ACCES model to predict the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis in Norway | Q40716390 | ||
| Quality of life measurement clarifies the cost-effectiveness of Helicobacter pylori eradication in peptic ulcer disease and uninvestigated dyspepsia | Q40721264 | ||
| NSAID induced gastrointestinal complications: the ARAMIS perspective--1997. Arthritis, Rheumatism, and Aging Medical Information System. | Q40858702 | ||
| Costs of medical care after first-ever stroke in The Netherlands | Q40971336 | ||
| Cost-utility analysis of thrombolytic therapy | Q41150227 | ||
| Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury | Q41757692 | ||
| Are selective COX 2 inhibitors superior to traditional NSAIDs? Rofecoxib did not provide unequivocal benefit over traditional NSAIDs | Q41933074 | ||
| Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? | Q42778090 | ||
| An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada | Q43560804 | ||
| Cost of stroke in Australia from a societal perspective: results from the North East Melbourne Stroke Incidence Study (NEMESIS). | Q43580548 | ||
| Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction | Q43802128 | ||
| Reporting of 6-month vs 12-month data in a clinical trial of celecoxib | Q43802162 | ||
| The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): Endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting | Q43904806 | ||
| Upper gastrointestinal tolerability of celecoxib compared with diclofenac in the treatment of osteoarthritis and rheumatoid arthritis | Q43916834 | ||
| Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac | Q43944829 | ||
| Lowering generic drug prices: less regulation equals more competition | Q44053865 | ||
| Prevention of complicated ulcer disease among chronic users of nonsteroidal anti-inflammatory drugs: the use of a nomogram in cost-effectiveness analysis | Q44175671 | ||
| COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease | Q44182620 | ||
| Arthritis treatment in Hong Kong--cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents | Q44230099 | ||
| Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis | Q44261800 | ||
| Cost-effectiveness of low dose corticosteroids versus non-steroidal anti-inflammatory drugs and COX-2 specific inhibitors in the long-term treatment of rheumatoid arthritis. | Q44267854 | ||
| Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly | Q44316505 | ||
| The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis | Q44470584 | ||
| Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis | Q44589069 | ||
| COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study | Q44813874 | ||
| Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults | Q44851038 | ||
| Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications | Q44960512 | ||
| Long-term follow-up of empirical treatment or prompt endoscopy for patients with persistent dyspeptic symptoms? | Q44981243 | ||
| Ten-year survival after first-ever stroke in the perth community stroke study | Q45084829 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | osteoarthritis | Q62736 |
| P304 | page(s) | 25 | |
| P577 | publication date | 2007-07-04 | |
| P1433 | published in | BMC Gastroenterology | Q15759922 |
| P1476 | title | An economic model of long-term use of celecoxib in patients with osteoarthritis | |
| P478 | volume | 7 |
| Q35533521 | 3,4-Dihydroxy-benzohydroxamic acid (Didox) suppresses pro-inflammatory profiles and oxidative stress in TLR4-activated RAW264.7 murine macrophages |
| Q28472098 | A comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an example |
| Q38038881 | A review of the efficacy, safety, and cost-effectiveness of COX-2 inhibitors for Africa and the Middle East region |
| Q34238267 | Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis |
| Q34584630 | Celecoxib: a review of its use in the management of arthritis and acute pain |
| Q34384075 | Cost-effectiveness analyses of osteoarthritis oral therapies: a systematic review |
| Q45347178 | Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective |
| Q46051343 | Economic evaluation of nonsteroidal anti-inflammatory drug strategies in rheumatoid arthritis |
| Q38042714 | Economic outcomes for celecoxib: a systematic review of pharmacoeconomic studies. |
| Q40041757 | Impact of patient sample on costs of events in pharmacoeconomic models. |
| Q35743672 | The cost-effectiveness of celecoxib versus non-steroidal anti-inflammatory drugs plus proton-pump inhibitors in the treatment of osteoarthritis in Saudi Arabia |
Search more.